HomeBlog Details

blog
Meticulous Research®

The name of our company defines our services, strengths, and values. Since the inception, we have endeavoured to research, analyze and present the critical market data with great attention to details.

Rising Burden of HAIs is Driving the Need for Sterilization Equipment

   October 15, 2024

The increasing prevalence of hospital-acquired infections (HAIs), the surge in surgical procedures, the need for sterilization in the food sector to combat foodborne illnesses, and the growing demand for sterilization equipment within the pharmaceutical and biotechnology industries underscore a critical market trend. HAIs, which manifest 48 hours or more after hospital admission or within 30 days post-discharge, are primarily caused by viral, bacterial, and fungal pathogens. Common forms of these infections include bloodstream infections, pneumonia, urinary tract infections (UTIs), and surgical site infections (SSIs). These infections pose significant risks to patient health and extend hospital stays, resulting in increased economic burdens for both patients and the healthcare system. In developed countries, HAIs account for approximately 7% of reported infections, while this figure rises to about 10% in developing nations. This article examines the surging demand for sterilization equipment and its associated benefits. 

Increasing Demand for Sterilization Equipment 

Companies in the pharmaceutical and biotechnology sectors are primary end users of sterilization technologies, which are crucial for ensuring sterile processing environments in manufacturing facilities. As these industries expand, the complexity of products being developed, such as biologics, gene therapies, and advanced therapeutics—continues to increase. 

The demand for biologics is rising due to their effectiveness in treating a variety of diseases. However, ensuring the sterile manufacturing of these sensitive molecules poses significant challenges for manufacturers. Biologics must be produced under aseptic conditions, typically utilizing sterile filtration, as they cannot endure traditional sterilization methods such as heat, chemical treatments, or radiation. Additionally, unit operations in sterile production, such as pumping, may damage and degrade biologics. Consequently, sterile manufacturing necessitates skilled professionals with in-depth knowledge of sterilization equipment. As a result, many pharmaceutical companies are increasingly choosing to outsource the sterilization of biologics to specialized providers. 

Use of Sterilization in Novel Therapies 

Novel therapies represent innovative treatment methods that have not been widely adopted, particularly for patients with conditions inadequately addressed by traditional treatments. These therapies encompass immunotherapies, cancer vaccines, gene and cell therapies, and stem cell therapies. Factors such as substantial funding, investments, and grants, advancements in genomics and other omics fields, a favorable environment for genomics research, and initiatives aimed at promoting personalized medicine are propelling the research and development of these novel therapies. Compared to conventional medicine, novel therapies significantly enhance patient outcomes, making them increasingly preferred for chronic and life-threatening diseases, including cancer, neurological disorders, rare diseases, and autoimmune conditions. The rising prevalence of complex ailments further fuels the demand for the development and implementation of novel therapies. 

The Center for Drug Evaluation and Research (CDER), a division of the U.S. Food and Drug Administration (FDA), evaluates the safety and efficacy of novel therapies. To maintain the quality of novel therapies, advanced disinfection, and sterilization methods are highly sought after. Some of the emerging sterilization approaches for various novel therapies include aseptic processing and single-use technologies.  

Growing Demand for Sterilization Products in Emerging Markets 

Recent technological advancements are creating significant growth opportunities for sterilization equipment in the healthcare sector across various emerging markets. India, recognized as one of the largest emerging markets for medical equipment globally, presents unique challenges and opportunities. While rural areas still face inadequate healthcare infrastructure, providers are increasingly utilizing refurbished medical devices as a cost-effective alternative to new equipment, thereby enhancing healthcare accessibility. 

In June 2023, the Government of India issued a notification allowing the import of refurbished medical devices, with the exception of critical care equipment. This regulation permits the import of 50 types of high-end, high-value devices, which is expected to boost the adoption of refurbished medical equipment in the country and drive market growth. For these refurbished devices, sterilization equipment is essential for disinfecting external surfaces, internal components, and reusable parts such as sensors and probes. 

Furthermore, over the last few years, the government of South Korea has been focusing on investing in pharmaceutical and biotech R&D. In 2019, the government launched a five-year plan for biotech-related research, development, and commercialization. The cash inflow is aimed at strengthening pharmaceutical and medical device manufacturing and exporting pharmaceutical products worth USD 50 billion by 2030. The increasing focus on pharmaceutical manufacturing is expected to drive the demand for sterilization equipment in the pharmaceutical industry. 

Singapore is rapidly establishing itself as a biopharmaceutical hub in the Asia-Pacific region. The country's economic development and investments in infrastructure to support biopharmaceutical manufacturing have attracted significant foreign investment. According to the Singapore Economic Development Board, 2020 saw the announcement of nearly 12 greenfield foreign direct investment projects in the life sciences sector, totaling a capital expenditure of USD 358 million. These developments aimed at enhancing biomanufacturing capacity in Singapore are anticipated to drive growth in the sterilization equipment market. 

Unlocking Sterilization Equipment: Insights from the Sterilization Equipment Market Analysis 

Recent insights from Meticulous Research® provide valuable perspectives on the future trajectory of the Sterilization Equipment Market. Projections suggest a potential worth of $26.77 billion by 2031, driven by a remarkable Compound Annual Growth Rate (CAGR) of 8% from 2024 to 2031.  

Notably, influential industry players, including STERIS plc (U.S.), Advanced Sterilization Products, Inc. (U.S.), Getinge AB (Sweden), and SteelcoBelimed AG (Switzerland), have established a broad presence worldwide, leading to the widespread adoption of sterilization equipment. This comprehensive overview from Meticulous Research serves as a gateway into the sterilization equipment market.  

Conclusion 

The rising adoption of sterilization equipment, coupled with the growing incidence of hospital-acquired infections, an increase in surgical procedures, and a heightened need for sterilization in the food industry to prevent foodborne diseases, is driving global demand. Furthermore, the trend of outsourcing sterilization processes to specialized service providers in non-healthcare sectors further contributes to the expanded use of these technologies worldwide. 

Access Full Report Here @  https://www.meticulousresearch.com/product/sterilization-equipment-market-5141/


Related Tag:

Related Blogs:
  Download Free Sample Report